<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508402</url>
  </required_header>
  <id_info>
    <org_study_id>KasrELAiniH</org_study_id>
    <nct_id>NCT02508402</nct_id>
  </id_info>
  <brief_title>Effect Of Intra-muscular Administration of Dexamethasone in Induction of Labour</brief_title>
  <official_title>Effect Of Intra-muscular Administration of Dexamethasone on the Duration of Induction of Labour in Primigravida Post-term Pregnancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABSTRACT:&#xD;
&#xD;
      Objective: To evaluate the efficacy of dexamethasone on labor duration and to establish&#xD;
      whether dexamethasone plays a role in shorting the duration interval between initiation of&#xD;
      labor induction and beginning of the active phase in primigravida full-term pregnancy.&#xD;
&#xD;
      Methods: case control study included 86 primigravidae with full term pregnancy classified&#xD;
      into two groups: The participant of Group I will receive a prefilled syringe with two&#xD;
      milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not&#xD;
      receive Dexamethasone or any other cervical ripening agent.&#xD;
&#xD;
      Key Words: Dexamethasone;post-term pregnancy;induction of labor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODS:&#xD;
&#xD;
      This retrospective clinical trial was conducted at the Department of Obstetrics and&#xD;
      Gynecology, Faculty of Medicine, Cairo University, during the period from August 2014 to May&#xD;
      2015. The study protocol was approved by the Scientific Research Committee, and informed&#xD;
      consent was obtained from all participants.&#xD;
&#xD;
      Each participant will randomly be assigned by computer list into Group I (Dexamethasone&#xD;
      group(n=43)and group II(control group(N=43).&#xD;
&#xD;
      No cervical ripening agent will be used for induction of labour in the trial.&#xD;
&#xD;
      Methodology in details:&#xD;
&#xD;
      I. The participant of Dexamethasone Group will receive a prefilled syringe with two&#xD;
      milliliters (8 mg) of Dexamethasone intramuscular, and the participants of placebo Group will&#xD;
      not receive Dexamethasone or any other cervical ripening agent.&#xD;
&#xD;
      All the participants in both groups will randomly be assigned by computer list. (Haijavandi&#xD;
      et., al 2013)&#xD;
&#xD;
      II. After six hours of the initial dose, the labour induction will start via Oxytocin using&#xD;
      the following protocol:&#xD;
&#xD;
        1. Initial dose of oxytocin.................................. 1 to 2 milliliter&#xD;
           international unit/min.&#xD;
&#xD;
        2. Increase interval......................................................30 minutes.&#xD;
&#xD;
        3. Dosage increment....................................................1 to 2 milliliter&#xD;
           international unit/min.&#xD;
&#xD;
        4. Usual dose for good labour.........................8 to12 milliliter international&#xD;
           unit/min.&#xD;
&#xD;
        5. Maximum dose…………………...................30 milliliter international unit/min. (Anne&#xD;
           Biringer et., al 2013).&#xD;
&#xD;
      III. The interval between the initiation of induction and the beginning of the active phase&#xD;
      of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a&#xD;
      10-minute span each last from 40-60 Sec).&#xD;
&#xD;
      IV. Partographic representation for progression of active phase labour:&#xD;
&#xD;
        1. Frequency and duration of uterine contraction.&#xD;
&#xD;
        2. Cervical dilatation will record every two hours by per vaginal examination.&#xD;
&#xD;
        3. Station and position of fetal head was noted at the same time.&#xD;
&#xD;
      V. After delivery:-&#xD;
&#xD;
        1. The duration of the first stage of labor will be recorded. (Partographic representation&#xD;
           will do for each participant).&#xD;
&#xD;
        2. The duration of the second stage of labor will be recorded.&#xD;
&#xD;
        3. The duration of the placental separation will be recorded.&#xD;
&#xD;
        4. The neonatal outcome will be recorded by APGAR score.&#xD;
&#xD;
        5. Any postpartum maternal adverse effect was noted (e.g. vital sign abnormality, any&#xD;
           maternal postpartum hemorrhage).&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      the duration between induction and beginning of active phase.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      -Duration of first stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the duration between induction and beginning of active phase.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of first stage.</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Medical Induction of Labor Affecting Fetus</condition>
  <arm_group>
    <arm_group_label>dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.&#xD;
All the participants in both groups will randomly be assigned by computer list.&#xD;
II. After six hours of the initial dose, the labour induction will start via Oxytocin using</description>
    <arm_group_label>dexamethasone group</arm_group_label>
    <other_name>epidrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two milliliters of normal saline given to placebo group .</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  Primigravida.&#xD;
&#xD;
          -  Post-term gestation i.e. 41 weeks or more.&#xD;
&#xD;
          -  Sure, reliable dates.&#xD;
&#xD;
          -  Favorable cervix with Bishop score of 7 or greater.&#xD;
&#xD;
          -  Longitudinal lie.&#xD;
&#xD;
          -  Cephalic presentation (Vertex).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal presentation.&#xD;
&#xD;
          -  Multigravida.&#xD;
&#xD;
          -  Multiple pregnancies.&#xD;
&#xD;
          -  Active phase of labour.&#xD;
&#xD;
          -  Cephalo-pelvic disproportion.&#xD;
&#xD;
          -  History of any medical disorder.&#xD;
&#xD;
          -  History of previous myomectomy operation.&#xD;
&#xD;
          -  Known contraindication or hypersensitivity to Dexamethasone.&#xD;
&#xD;
          -  Current fetal distress.&#xD;
&#xD;
          -  Current maternal or fetal disorder e.g. Diabetes mellitus; Pregnancy induced&#xD;
             hypertension, and fetal growth retardation.&#xD;
&#xD;
          -  Over distended abdomen e.g. fetal macrosomia or polyhydramnios suggested by ultrasound&#xD;
             or estimated fetal weight by expert hand.&#xD;
&#xD;
          -  Significant vaginal bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mohamed Abdel Aziz El Sharkawy</name>
      <address>
        <city>Cairo</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed El-Sharkawy</investigator_full_name>
    <investigator_title>Lecturer of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

